The application of targeted drugs for breast cancer is based on whether the patient has a certificate of applicability for the use of the drug, not on whether the patient has metastasis. At present, the most widely used targeted drugs for breast cancer are anti-HER-2 gene targeted drugs, commonly used drugs include trastuzumab, patuximab and neratinib. The use of targeted drugs is based on whether the patient has a certificate of applicability for the drug, for example, anti-HER-2 drugs are based on whether the patient’s cancer cells express HER-2 receptors on their surface. Regardless of whether the cancer cells have metastasized or not, as long as the cancer cells have the corresponding receptors, the targeted drugs can be used. Besides, the specific use of targeted drugs must be under the guidance of oncologists.